Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study

被引:21
|
作者
Spadea, A. [1 ]
Unim, B. [2 ]
Colamesta, V. [2 ]
Meneghini, A. [1 ]
D'Amici, A. M. [1 ]
Giudiceandrea, B. [1 ]
La Torre, G. [2 ,3 ]
机构
[1] RM A Local Hlth Unit, Rome, Italy
[2] Univ Roma La Sapienza, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy
[3] Eleonora Lorillard Spencer Cenci Fdn, Rome, Italy
关键词
TIV; MF59; ATIV; Elderly; Influenza; Hospitalization; ANTIBODY-RESPONSE; HEALTH; HOSPITALIZATION; COMMUNITY; MORTALITY; CHILDREN; SAFETY;
D O I
10.1016/j.vaccine.2014.07.077
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Influenza illness is an important public health problem and annual vaccination is globally recommended for high risk populations. Objective: The aim was to evaluate and compare the effectiveness of influenza vaccines in reducing hospitalizations for influenza or pneumonia during two influenza seasons in the elderly. Methods: A case-control study was performed, using administrative database of the Local Health Unit Roma-A (LHU RM-A). The included subjects were at least 65 years old and residing in one of the four districts of the LHU. The cases were hospitalized for influenza or pneumonia during influenza season in the years 2010-2011 and 2011-2012. The controls were hospitalized in the same period, but not for influenza or pneumonia. The subjects were immunized with the trivalent inactivated influenza vaccine (TIV) in the first influenza season (2010-2011) and with the adjuvanted influenza vaccine MF59 (ATIV) in the second season (2011-2012). Results: A total of 269 cases and 1247 controls were included for the 2010-2011 influenza season, and 365 cases and 1227 controls were selected for the 2011-2012 season. Up to 63.6% cases and 53.5% controls in the 2010-2011 season and 78.6% of cases and 64.1% of controls in the 2011-2012 season have not been vaccinated. Female gender and high educational level were protective factors for hospitalization. Subjects over 75 years were at high risk of hospitalization compared to 65-74 years olds. Influenza vaccination reduced significantly hospitalization in both seasons. In subjects with 65-74 years TIV was more effective than ATIV; vice versa for those over 75 years old. Discussion and conclusion: TIV and ATIV reduce hospitalization for influenza or pneumonia with a variable degree of protection in different age groups. In particular, ATIV is more effective in individuals over 75 years old. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5290 / 5294
页数:5
相关论文
共 50 条
  • [31] Efficacy of Injectable Trivalent Virosomal-Adjuvanted Inactivated Influenza Vaccine in Preventing Acute Otitis Media in Children With Recurrent Complicated or Noncomplicated Acute Otitis Media
    Marchisio, Paola
    Esposito, Susanna
    Bianchini, Sonia
    Dusi, Elisa
    Fusi, Michela
    Nazzari, Erica
    Picchi, Raffaella
    Galeone, Carlotta
    Principi, Nicola
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (10) : 855 - 859
  • [32] Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study
    Vesikari, Timo
    Nauta, Jos
    Lapini, Giulia
    Montomoli, Emanuele
    van de Witte, Serge
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 92 : 29 - 37
  • [33] A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
    Haugh, Margaret
    Gresset-Bourgeois, Viviane
    Macabeo, Berengere
    Woods, Anne
    Samson, Sandrine I.
    EXPERT REVIEW OF VACCINES, 2017, 16 (06) : 545 - 564
  • [34] Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine A randomized study in US adults
    Campbell, James D.
    Chambers, Christopher V.
    Brady, Rebecca C.
    Caldwell, Michael C.
    Bennett, Nathan L.
    Fourneau, Marc A.
    Jain, Varsha K.
    Innis, Bruce L.
    HUMAN VACCINES, 2011, 7 (01): : 81 - 88
  • [35] A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
    Carmona Martinez, Alfonso
    Salamanca de la Cueva, Ignacio
    Boutet, Philippe
    Vanden Abeele, Carline
    Smolenov, Igor
    Devaster, Jeanne-Marie
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1959 - 1968
  • [36] Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children A Case-Control Study
    Kelly, Heath
    Jacoby, Peter
    Dixon, Gabriela A.
    Carcione, Dale
    Williams, Simon
    Moore, Hannah C.
    Smith, David W.
    Keil, Anthony D.
    Van Buynder, Paul
    Richmond, Peter C.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (02) : 107 - 111
  • [37] Effectiveness of rotavirus vaccine against hospitalized rotavirus diarrhea: A case-control study
    Ichihara, Maria Y. T.
    Rodrigues, Laura C.
    Santos, Carlos A. S. Teles
    Teixeira, Maria da Gloria L. C.
    De Jesus, Sandra R.
    De Matos, Sheila M. Alvim
    Leite, Jose P. Gagliardi
    Barreto, Mauricio L.
    VACCINE, 2014, 32 (23) : 2740 - 2747
  • [38] Effectiveness of monovalent rotavirus vaccine in Bolivia: case-control study
    Patel, Manish M.
    Patzi, Maritza
    Pastor, Desiree
    Nina, Aleida
    Roca, Yelin
    Alvarez, Leovigildo
    Iniguez, Volga
    Rivera, Rosario
    Tam, Ka Ian
    Quaye, Osbourne
    Bowen, Michael
    Parashar, Umesh
    De Oliveira, Lucia Helena
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [39] Effectiveness of the monovalent rotavirus vaccine in Colombia: A case-control study
    Cotes-Cantillo, Karol
    Paternina-Caicedo, Angel
    Coronell-Rodriguez, Wilfrido
    Alvis-Guzman, Nelson
    Parashar, Umesh D.
    Patel, Manish
    De la Hoz-Restrepo, Fernando
    VACCINE, 2014, 32 (25) : 3035 - 3040
  • [40] Trivalent Inactivated Influenza Virus Vaccine Given to Two-Month-Old Children An Off-Season Pilot Study
    Walter, Emmanuel B.
    Englund, Janet A.
    Blatter, Mark
    Nyberg, Jack
    Ruben, Frederick L.
    Decker, Michael D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (12) : 1099 - 1104